Selected Publications

Liang M, Zhao Y, Lin D, Cooperberg M, Zheng Y*. Estimating optimal tailored active surveillance strategy under interval censoring.  Biometrics 2025;81(2):ujaf067. PMCID: PMC12123698

Chung Y, Cai T, Newcomb L, Lin D, Zheng Y*. Improving Efficiency and Robustness of the Prognostic Accuracy of Biomarkers with Partial Incomplete Failure-Time Data and Surrogate Outcome: Application to Prostate Cancer Active Surveillance Study.  Statistics in Medicine 2025;44(8-9):e70072. (* corresponding author) PMID: 40277348

Zhao, Y., Gulati, R., Lange, J., Olivas-Martinez, A., Raoof, S, Zheng, Y., Feng, Z., and Etzioni, R. Sensitivity Measures in Studies of Cancer Early Detection Biomarkers. CCancer Epidemiology, Biomarkers and  Prevention 2025;34(6):944-951. PMID: 40208630 PMCID: PMC12135019

Zheng, Y., Wagner, P.D., Singal, A.G., Hanash, S.M., Srivastava, S., Huang, Y., Zhao, Y.Q., Chari, S.T., Marquez, G., Marsh, T.L. and Feng, Z., 2024. Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers. Cancer Epidemiology, Biomarkers and  Prevention 2024;33(9), pp.1150-1157. PMCID: PMC11534000

Goss, L.B., Liu, M., Zheng, Y., Guo, B., Conti, D.V., Haiman, C.A., Kachuri, L., Catalona, W.J., Witte, J.S., Lin, D.W. and Newcomb, L.F., 2025. Polygenic risk score and upgrading in patients with prostate cancer receiving active surveillance. Journal of the American Medical Association Oncology, 11(2), pp.168-171. PMID: 39666350 PMCID: PMC11843374

Zhu K, Zhao Y, & Zheng Y*., Designing cancer screening trials for the late-stage cancer incidence reduction, Biometrics 2024;80(3) (*corresponding author) PMID: 39302139 PMCID: PMC11413908

Newcomb L., Schenk J., Zheng Y., … Nelson P., and Lin D. (2024) Long term outcomes in patients using protocol-directed active surveillance for prostate cancer. Journal of the American Medical Association 2024;331(24):2084-2093. PMCID: PMC11140579

Tosoian JJ, Zhang Y, Xiao L, …Zheng Y, Wei J, Chinnaiyan A., (2024) Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. Journal of the American Medical Association Oncology 2024;10(6):726-736. doi: 10.1001/jamaoncol.2024.0455. PMCID: PMC11190811

Etzioni R, Gulati R, Patriotis C, Rutter C, Zheng Y, Srivastava S, et al. Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. JNCI: Journal of the National Cancer Institute 2024;116(2):189-93. PMCID: PMC10852609

Dong X, Zheng Y, Lin D, Newcomb L, Zhao Y. Constructing stabilized dynamic surveillance rules for optimal monitoring schedules. Biometrics 2023;79(4):3895-3906. PMCID: PMC10866138

Cao Y, Haneuse S, Zheng Y, Chen J. Two-phase stratified sampling and analysis for predicting binary outcomes. Biostatistics 2023;24(3):585-602. PMCID: PMC10345986

Beaber E, Burnett-Hartman A, Hixon B, Kobrin S, Li C, Oliver M, Rendle K, Skinner CS, Todd K, Zheng Y, Ziebell R, Breslau E, Chubak J, Corley D, Greenlee R, Haas J, Halm E, Honda S, Nesland-Dudas C, Ritzwoller D, Schottinger JE, Tiro J, Vachani A, Doria-Rose P. Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidem Biomarkers Prev 2022;31(8):1521-1531. PMCID: PMC9350927

Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer 2022;128(2):269-274. PMCID: PMC8738121

Zheng J, Zheng Y, Hsu L. Re-calibrating Pure Risk Integrating Individual Data from Two-Phase Studies with External Summary Statistics. Biometrics 2022;78(4):1515-1529. PMCID: PMC8895713

Wang X, Zheng Y, Jensen MK, He Z, Cai T. Biomarker evaluation under imperfect nested case-control design. Statistics in Medicine 2021;40(18):4035-52. PMCID: PMC8286316

Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP. Evaluating the outcomes of active surveillance in grade group 2 prostate cancer: prospective results from the Canary PASS cohort. The Journal of Urology 2021;2:10-97. PMCID: PMC8917057

Zheng J, Zheng Y, Hsu L. Risk projection for time-to-event outcome leveraging summary statistics with source individual-level data. Journal of the American Statistical Association 2021;21:1-3. PMCID: PMC9855229

Chan S, Wang X, Jazic I, Peskoe S, Zheng Y, Cai T. Developing and evaluating risk prediction models with panel current status data. Biometrics 2021;77(2):599-609. PMCID: PMC8168594

Wang Y, Zhao YQ, Zheng Y*. Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint. Biometrics 2020;76(3):853-862. (*corresponding author) PMCID: PMC7292743.

Cooperberg M, Zheng Y, Faino AV Newcomb L, Zhu K, Cowan J, Brooks J, Dash A, Gleave M, Martin F, Morgan T, Nelson P, Thompson I, Wagner A, Carroll P, Lin D. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. Journal of the American Medical Association Oncology 2020;6(10):e203187. PMCID: PMC7453344.

 Lin D, Zheng Y, McKenney J, Brown M, Lu R, Crager M, Boyer H, Tretiakova M, Brooks J,Dash A, Fabrizio M, Gleave M, Kolb S, Liss M, Morgan T, Thompson I, Wagner A, Tsiatis A, Pingitore A, Nelson P, Newcomb L. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology 2020;38(14):1549-1557. PMCID: PMC7213589.

Liu D, Cai T, Lok A, and Zheng Y. Nonparametric maximum likelihood estimators of time-dependent accuracy measures for survival outcome under two-stage sampling designs. Journal of the American Statistical Association 2018;113(522):882-892. PMCID: PMC6291304. 

Lin D, Newcomb L, Brown M, Sjoberg D, Dong Y, Brook J, Carroll P, Cooperberg M, Dash A, Ellis W, Fabrizio M, Gleave M, Morgan T, Nelson P, Thompson I, Wagner A and Zheng Y. Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the Canary Prostate Active Surveillance Study (PASS). European Urology 2017;72(3):448-454. PMCID: PMC7327706

Maziarz M, Heagerty P, Cai T, and Zheng Y*. On longitudinal prediction with time-to-event outcome: Comparison of modeling options. Biometrics 2017;73(1):83–93 (*corresponding author) PMCID: PMC5250577.

Liu D, Zheng Y, Prentice R, Hsu L. Estimating risk with time-to-event data: an application to the Women's Health Initiative. Journal of the American Statistical Association 2014;109(506):514–524. PMCID: PMC4091861

Cai T. and Zheng Y. Resampling Procedures for Making Inference under Nested Case-control Studies. Journal of the American Statistical Association 2013;108(504):1532-1544. PMCID: PMC3891801.

Zheng Y, Cai T, Pepe MS. Adopting nested case-control quota sampling designs for the evaluation of risk markers. Lifetime Data Analysis 2013;19(4):568-588. PMCID: PMC3903399.

Liu D, Cai T, Zheng Y*. Evaluating the Predictive Value of Biomarkers with Stratified Case-Cohort Design. Biometrics. 2012;68(4):1219-27. PMCID: PMC3718317.

Zheng Y, Cai T, Jin Y, Feng Z. Evaluating prognostic accuracy of biomarkers under competing risk. Biometrics 2012;68(2):388-96.   PMCID: PMC3694786.

Zheng Y, Cai T, Stanford J, and Feng Z. Semiparametric models of time-dependent predictive values of prognostic biomarkers. Biometrics. 2010;66:50-60. PMCID: PMC2875380.

Zheng Y, Cai T, Pepe MS, Levy, W. Time-dependent predictive values of prognostic biomarkers with failure time outcome. Journal of the American Statistical Association 2008;103:362-368. PMCID: PMC2719907.

Zheng Y, Katsaros D, Shan S, Longrais I, Porpiglia M, Scorilas A, Kim N, Wolfert R, Simon I, Li L, Feng Z, Diamandis E. A multiparametric panel for ovarian cancer diagnosis, prognosis and response to chemotherapy. Clinical Cancer Research.2007;13(23):6993-7002. PMID: 18056174.

Zheng Y, Heagerty P.  Prospective accuracy for longitudinal markers. Biometrics 2007; 63(2), 332-341. PMID: 17688486

Zheng Y, Cai T, Feng Z. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 2006;62(1): 279-287. PMID: 16542256.

Zheng Y, Heagerty P. Partly conditional survival model for longitudinal data. Biometrics 2005;61(2):379-391. PMID: 16011684

Zheng Y, Heagerty P. Semiparametric estimation of time-dependent ROC curves for longitudinal marker data. Biostatistics 2004;5(4): 615-632. PMID: 15475423